37th Annual San Antonio Breast Cancer Symposium. Resumen de las aportaciones translacionales y clínicas más relevantes
作者： Marta Santisteban , Susana de la Cruz , Jaime Espinós , Jose M. Aramendía , Oscar A. Fernández-Hidalgo
DOI: 10.1016/J.SENOL.2015.02.001
关键词:
摘要: Resumen En diciembre de 2014 hemos tenido la oportunidad ampliar nuestro conocimiento en el Simposio Internacional Cancer Mama, celebrado San Antonio, resaltando: 1) escenario basico, adquisicion mutaciones durante proceso carcinogenesis y metastasis, aumentando clonalidad heterogeneidad tumoral, papel pronostico los neoantigenos linfocitos infiltrantes residuo tumoral tras neoadyuvancia, asi como mayor alteraciones receptor estrogeno asociadas a hormonorresistencia; 2) translacional, empleo xenoinjertos derivados tumores pacientes modelos murinos para evitar las resistencias terapeuticas, biomarcadores liquidos descartar enfermedad minima residual cancer mama precoz; 3) clinica resultados tanto prevencion adyuvancia con hormonoterapia, quimioterapia triples negativos novedades inmunoterapia.
elsevier.es
elsevier.com参考文章(25)
Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill, Joan Bradbury, Michael Clarke, Rory Collins, Susan R Davis, Antonella Delmestri, John F Forbes, Peiman Haddad, Ming-Feng Hou, Moshe Inbar, Hussein Khaled, Joanna Kielanowska, Wing-Hong Kwan, Beela S Mathew, Indraneel Mittra, Bettina Müller, Antonio Nicolucci, Octavio Peralta, Fany Pernas, Lubos Petruzelka, Tadeusz Pienkowski, Ramachandran Radhika, Balakrishnan Rajan, Maryna T Rubach, Sera Tort, Gerard Urrútia, Miriam Valentini, Yaochen Wang, Richard Peto, None, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial The Lancet. ,vol. 381, pp. 805- 816 ,(2013) , 10.1016/S0140-6736(12)61963-1
C.G. Drake, Combination immunotherapy approaches Annals of Oncology. ,vol. 23, ,(2012) , 10.1093/ANNONC/MDS262
C. Verslype, O. Rosmorduc, P. Rougier, Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology. ,vol. 23, pp. 41- 48 ,(2012) , 10.1093/ANNONC/MDS225
Prudence A Francis, Meredith M Regan, Gini F Fleming, István Láng, Eva Ciruelos, Meritxell Bellet, Hervé R Bonnefoi, Miguel A Climent, Gian Antonio Da Prada, Harold J Burstein, Silvana Martino, Nancy E Davidson, Charles E Geyer Jr, Barbara A Walley, Robert Coleman, Pierre Kerbrat, Stefan Buchholz, James N Ingle, Eric P Winer, Manuela Rabaglio-Poretti, Rudolf Maibach, Barbara Ruepp, Anita Giobbie-Hurder, Karen N Price, Marco Colleoni, Giuseppe Viale, Alan S Coates, Aron Goldhirsch, Richard D Gelber, None, Adjuvant ovarian suppression in premenopausal breast cancer The New England Journal of Medicine. ,vol. 372, pp. 436- 446 ,(2015) , 10.1056/NEJMOA1412379
M.V. Dieci, C. Criscitiello, A. Goubar, G. Viale, P. Conte, V. Guarneri, G. Ficarra, M.C. Mathieu, S. Delaloge, G. Curigliano, F. Andre, Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study Annals of Oncology. ,vol. 25, pp. 611- 618 ,(2014) , 10.1093/ANNONC/MDT556
Ivana Sestak, Jack Cuzick, Mitch Dowsett, Elena Lopez-Knowles, Martin Filipits, Peter Dubsky, John Wayne Cowens, Sean Ferree, Carl Schaper, Christian Fesl, Michael Gnant, None, Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score Journal of Clinical Oncology. ,vol. 33, pp. 916- 922 ,(2015) , 10.1200/JCO.2014.55.6894
Circulating tumor DNA to monitor metastatic breast cancer. The New England Journal of Medicine. ,vol. 369, pp. 93- 94 ,(2013) , 10.1056/NEJMC1306040
Philip J Stephens, Patrick S Tarpey, Helen Davies, Peter Van Loo, Chris Greenman, David C Wedge, Serena Nik-Zainal, Sancha Martin, Ignacio Varela, Graham R Bignell, Lucy R Yates, Elli Papaemmanuil, David Beare, Adam Butler, Angela Cheverton, John Gamble, Jonathan Hinton, Mingming Jia, Alagu Jayakumar, David Jones, Calli Latimer, King Wai Lau, Stuart McLaren, David J McBride, Andrew Menzies, Laura Mudie, Keiran Raine, Roland Rad, Michael Spencer Chapman, Jon Teague, Douglas Easton, Anita Langerød, Oslo Breast Cancer Consortium (OSBREAC) Karesen Rolf 34 35 Schlichting Ellen 34 Naume Bjorn 35 36 Sauer Torill 35 37 Ottestad Lars 36, Ming Ta Michael Lee, Chen-Yang Shen, Benita Tan Kiat Tee, Bernice Wong Huimin, Annegien Broeks, Ana Cristina Vargas, Gulisa Turashvili, John Martens, Aquila Fatima, Penelope Miron, Suet-Feung Chin, Gilles Thomas, Sandrine Boyault, Odette Mariani, Sunil R Lakhani, Marc van de Vijver, Laura van ‘t Veer, John Foekens, Christine Desmedt, Christos Sotiriou, Andrew Tutt, Carlos Caldas, Jorge S Reis-Filho, Samuel AJR Aparicio, Anne Vincent Salomon, Anne-Lise Børresen-Dale, Andrea L Richardson, Peter J Campbell, P Andrew Futreal, Michael R Stratton, None, The landscape of cancer genes and mutational processes in breast cancer Nature. ,vol. 486, pp. 400- 404 ,(2012) , 10.1038/NATURE11017
Steffi Oesterreich, Nancy E Davidson, The search for ESR1 mutations in breast cancer Nature Genetics. ,vol. 45, pp. 1415- 1416 ,(2013) , 10.1038/NG.2831
Stanislas Du Manoir, Béatrice Orsetti, Rui Bras-Gonçalves, Tien-Tuan Nguyen, Laurence Lasorsa, Florence Boissière, Blandine Massemin, Pierre-Emmanuel Colombo, Frédéric Bibeau, William Jacot, Charles Theillet, None, Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Molecular Oncology. ,vol. 8, pp. 431- 443 ,(2014) , 10.1016/J.MOLONC.2013.11.010